Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash Flows from Operating Activities
Net income	$ 2,408.4	$ 2,390.5	$ 4,684.8
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Depreciation and amortization	1,427.7	1,379.0	1,445.6
Change in deferred income taxes	(748.4)	36.8	265.9
Stock-based compensation expense	217.8	156.0	144.9
Acquired in-process research and development	535.0	200.2	57.1
Income related to termination of the exenatide collaboration with Amylin	0.0	0.0	(495.4)
Net proceeds from (payments for) terminations of interest rate swaps	(186.1)	340.7	0.0
Other non-cash operating activities, net	36.4	13.8	25.1
Other changes in operating assets and liabilities, net of acquisitions and divestitures:
Receivables - (increase) decrease	(304.5)	117.4	(152.7)
Inventories - (increase) decrease	(736.3)	(307.1)	(286.5)
Other assets - (increase) decrease	(338.8)	411.5	116.5
Accounts payable and other liabilties-increase (decrease)	461.6	(371.7)	(70.3)
Net Cash Provided by Operating Activities	2,772.8	4,367.1	5,735.0
Cash Flows from Investing Activities
Purchases of property and equipment	(1,066.2)	(1,162.6)	(1,012.1)
Disposals of property and equipment	92.6	15.3	179.4
Cash released (restricted) for pending acquisition	5,405.6	(5,405.6)	0.0
Proceeds from sales and maturities of short-term investments	2,161.8	4,054.1	3,320.1
Purchases of short-term investments	(842.2)	(1,637.8)	(1,531.0)
Proceeds from sales of noncurrent investments	3,068.4	11,009.4	11,235.0
Purchases of noncurrent investments	(3,226.5)	(9,802.7)	(14,041.9)
Proceeds from sale of product rights	410.0	0.0	0.0
Purchase of product rights	0.0	(308.3)	(24.1)
Purchases of in-process research and development	(560.0)	(95.0)	(57.1)
Cash paid for acquisitions, net of cash acquired	(5,283.1)	(551.4)	(43.7)
Other investing activities, net	(133.6)	(24.5)	(97.4)
Net Cash Provided by (Used for) Investing Activities	26.8	(3,909.1)	(2,072.8)
Cash Flows from Financing Activities
Dividends paid	(2,127.3)	(2,101.2)	(2,120.7)
Net change in short-term borrowings	(2,680.6)	2,680.6	0.0
Proceeds from issuance of long-term debt	4,454.7	992.9	0.0
Repayments of long-term debt	(1,955.7)	(1,034.8)	(10.5)
Purchases of common stock	(749.5)	(800.0)	(1,698.1)
Other financing activities, net	139.2	187.4	0.0
Net Cash Used for Financing Activities	(2,919.2)	(75.1)	(3,829.3)
Effect of exchange rate changes on cash and cash equivalents	(85.6)	(341.5)	(21.5)
Net increase (decrease) in cash and cash equivalents	(205.2)	41.4	(188.6)
Cash and cash equivalents at beginning of year	3,871.6	3,830.2	4,018.8
Cash and Cash Equivalents at End of Year	$ 3,666.4	$ 3,871.6	$ 3,830.2